Swedish pharmaceutical firm NeuroVive Pharmaceutical has appointed Erik Kinnman as its new chief executive officer, replacing interim CEO Jan Nilsson who will resume his position as chief operating officer.
Kinnman brings twenty years of experience in business and clinical development as well as investor relations and strategy to the role having held senior leadership positions at several pharmaceutical companies, including Pfizer and Sanofi.
He joins NeuroVive from his consultancy, Kinnman Life Science Solutions, where he served as chief executive officer and chief operating officer from 2011 until March this year.
Prior to this, Kinnman was director of investor relations and business strategy at Sobi from 2008 until 2011 and medical director at AstraZeneca from 2003 to 2008.
Gregory Batcheller, chairman of the NeuroVive board of directors, said: “The NeuroVive board and I are confident that Erik Kinnmann is the right person to lead the company, its strategy, and leverage the opportunities.
“The combination of his strategic vision and medical expertise is an excellent fit with NeuroVive’s strategy refocused towards R&D.”
Kinnman said: “I am excited about NeuroVive, the CEO role, and the opportunity to contribute to the success and growth of the company.
“NeuroVive is a highly innovative organisation and I am convinced that it has great potential in its range of novel treatment opportunities and their commercial potential.”